state council

State Council Legislative Priorities Highlight Key Issues for 2018

The General Office of the State Council’s legislative work plan for 2018 indicates that several policies affecting foreign companies may be revised this year, including foreign investment restrictions, ecommerce, tax, and environmental regulations.

Tags

China’s new leadership largely as expected, though prospects for reform remain unclear

China’s legislature over the weekend and today approved a new round of leaders for the State Council and its ministries. The appointments put some reform-minded officials in key roles, but whether that leads to faster movement on economic reforms remains to be seen.

Tags

NPC

What to expect in the final National People’s Congress meeting

China’s legislative body is expected to deviate from the typical economic agenda when it convenes March 5 for its final session before the 19th Communist Party Congress in the fall. Instead, the focus will be on preparing for the Party Congress and a leadership shuffle for President Xi Jinping’s second five-year term.

Tags

NPC
5YP

New Year, New High-Level Leadership Changes

The start of 2016 brought several personnel shifts in China’s central government, including in agencies responsible for publishing economic data and for taxation, financial system, and state-owned enterprise (SOE) regulation.

Notable recent personnel changes include:

Tags

Does the New Market Access Negative List System Indicate Opening Up?

China has announced further details about plans to gradually decrease government control over investment decisions. The Opinions on Implementing the Market Access Negative List System, a document released by the State Council on October 19, 2015, offer a firmer roadmap towards adopting a “negative list” approach in China, which would allow foreign investment in all fields except those expressly restricted.

Tags

Sweeping Changes Underway for China’s Drug and Medical Device Approvals

Hindered by redundancies in the approval process, problems securing suitable data for clinical trials, and disparities in the drug classification system between China and other countries, foreign companies have rarely found it easy to navigate China’s lengthy regulatory framework for approving pharmaceuticals and medical devices.

Tags

Pages

Subscribe to RSS - state council